FDA Kidney Warning for Orlistat (Alli/Xenical): Symptoms to Know

The FDA approved new warning language for the OTC weight-loss drug alli (orlistat 60 mg) on June 10, 2026. The update highlights a rare risk of acute kidney injury and kidney stones and adds a practical symptom checklist for people using orlistat.

If you (or someone you care for) has a history of kidney disease or kidney stones, this labeling change is a reminder to talk with a health care professional before starting—so you know what to watch for and when to get help.

What changed in the OTC alli label

In its Drug Safety Communication, the FDA states that the Drugs Facts Label for OTC alli was updated to:

Advise consumers to ask a health care provider before using alli if they have ever had kidney disease or kidney stones.
Tell consumers to stop using alli and ask a doctor if they develop symptoms that can signal kidney injury or kidney stones.

The FDA lists these symptom examples:

Back or groin pain
Painful urination
Blood in the urine
Feet and leg swelling
Less frequent urination

How this applies to prescription Xenical

Prescription Xenical contains the same active ingredient (orlistat) at a higher dose (120 mg). The FDA says the risk of renal (kidney) injury is now described consistently across the labeling for all FDA-approved orlistat products, including OTC and prescription products.

Who may be at higher risk

The FDA’s label change specifically emphasizes people with a history of kidney disease or kidney stones. In the FDA’s postmarketing review of kidney complication reports associated with alli use (search dates from February 9, 2007 through December 31, 2023), the agency identified:

12 cases of kidney complications (nine from the FDA Adverse Event Monitoring System and three from the literature)
Median patient age 61 years (range 36–76) and slightly more females (7) than males (5)
A mix of kidney complication types: 8 acute kidney injury, 2 acute kidney injury with oxalate nephropathy, and 2 hyperoxaluria with calcium oxalate kidney stones

Symptom checklist: what to watch for

If you develop the FDA-listed symptoms (back/groin pain, painful urination, blood in the urine, feet/leg swelling, or urinating less often) while taking orlistat, treat this as a potential kidney warning sign.

What to do (practical next steps)

If you’re taking OTC alli: the FDA label instructs you to stop taking alli and consult a health care provider for further guidance.
If you’re taking prescription Xenical: contact your prescribing clinician promptly and ask about next steps. If symptoms are severe or you can’t reach care quickly, seek urgent/emergency medical care as you would for any serious health concern.

What’s known vs. what’s still uncertain

The FDA notes that the risk information is based on postmarketing case reports, which have important limits:

How often this happens is uncertain: the actual number of cases could be higher because side effects don’t always get reported.
Some reports lacked key clinical details, such as stone composition and prior medical history.
Other factors may have contributed: the FDA reports that several people had possible alternative explanations (for example, obesity, diabetes, high blood pressure, and a history of kidney disease or kidney stones).

In the identified cases, the FDA also reported substantial outcomes: 8 patients required hospitalization and 5 required dialysis. The FDA further states its analysis suggests orlistat-associated oxalate nephropathy and kidney injury may not be dose-dependent—the risk may exist at both the 60 mg OTC dose and the 120 mg prescription dose.

Bottom line for readers and caregivers

Before starting orlistat (OTC alli or prescription Xenical), ask your clinician or pharmacist if you have kidney disease or kidney stones.
Keep the symptom checklist handy and watch for urinary changes, flank/back or groin pain, and swelling.
If symptoms appear: for alli, follow the label instruction to stop and seek medical guidance; for Xenical, contact your prescriber promptly.

Clinician-adjacent takeaway: FDA’s update reinforces kidney history screening and symptom-triggered evaluation for patients using orlistat. The agency’s identified cases included severe outcomes, even though causality and true risk frequency cannot be determined from spontaneous reports alone.

Weight-loss planning still matters

CDC emphasizes that healthy weight loss is a plan-based lifestyle approach (healthy eating patterns, regular physical activity, enough sleep, and stress management) and that if you have questions about weight-loss options or medications, you should talk with a health care provider.

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.